VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis

Clinical and Experimental Immunology

Volumn 175, Issue 1, 2014, Pages 126-137

  Mendel, I ^a   Feige, E ^a   Yacov, N ^a   Salem, Y ^a   Levi, I ^a   Propheta Meiran, O ^a   Shoham, A ^a   Ishai, E ^a   George, J ^a   Harats, D ^a   Breitbart, E ^a  

^a VBL Therapeutics   (Israel)

Author keywords

Atherosclerosis; Monocytes; Oxidized phospholipids

Indexed keywords

ANTIINFLAMMATORY AGENT; ATORVASTATIN; CD14 ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VB 201;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RABBIT MODEL; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; MONOCYTES; OXIDIZED PHOSPHOLIPIDS;

ANIMALS; ANTIGENS, CD14; ATHEROSCLEROSIS; CHOLESTEROL; GLYCERYLPHOSPHORYLCHOLINE; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; MALE; MICE; MONOCYTES; RABBITS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84888873120     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12212     Document Type: Article

References (42)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793-795.
4. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219:187-203.
5. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010; 134:33-46.
6. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8:802-815.
7. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 2008; 200:239-246.
8. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26:2421-2432.
9. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99:2752-2761.
10. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92:8264-8268.
11. Kunjathoor VV, Febbraio M, Podrez EA etal. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277:49982-49988.
12. Webb NR, Moore KJ. Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr Drug Targets 2007; 8:1249-1263.
13. Yamashita S, Hirano K, Kuwasako T etal. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem 2007; 299:19-22.
14. Febbraio M, Podrez EA, Smith JD etal. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105:1049-1056.
15. Podrez EA, Febbraio M, Sheibani N etal. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105:1095-1108.
16. Boullier A, Gillotte KL, Horkko S etal. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000; 275:9163-9169.
17. Berliner JA, Territo MC, Sevanian A etal. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85:1260-1266.
18. Lee H, Shi W, Tontonoz P etal. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000; 87:516-521.
19. Stewart CR, Stuart LM, Wilkinson K etal. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-161.
20. Walton KA, Hsieh X, Gharavi N etal. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003; 278:29661-29666.
21. Blasius AL, Beutler B. Intracellular Toll-like receptors. Immunity 2010; 32:305-315.
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
23. O'Neill LA. When signaling pathways collide: positive and negative regulation of Toll-like receptor signal transduction. Immunity 2008; 29:12-20.
24. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-650.
25. Jin MS, Kim SE, Heo JY etal. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130:1071-1082.
26. Kang JY, Nan X, Jin MS etal. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009; 31:873-884.
27. Kim JI, Lee CJ, Jin MS etal. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005; 280:11347-11351.
28. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81.
29. Seyerl M, Bluml S, Kirchberger S etal. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol 2008; 38:778-787.
30. Bluml S, Kirchberger S, Bochkov VN etal. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 2005; 175:501-508.
31. Bluml S, Zupkovitz G, Kirchberger S etal. Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids. Blood 2009; 114:5481-5489.
32. Mendel I, Shoham A, Propheta-Meiran O etal. A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. J Neuroimmunol 2010; 226:126-135.
33. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized phospholipid inhibition of Toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 2008; 283:24748-24759.
34. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27:165-197.
35. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17:1410-1422.
36. Xu XH, Shah PK, Faure E etal. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104:3103-3108.
37. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158-1161.
38. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278:1561-1568.
39. Seimon TA, Nadolski MJ, Liao X etal. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010; 12:467-482.
40. Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY, Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993; 28:599-605.
41. Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLOS ONE 2008; 3:e3204.
42. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005; 115:3149-3156.